News & Trends - Pharmaceuticals
Former NSW Premier criticises Covid vaccine mandates in final speech

Pharma News: Former New South Wales Liberal Premier Dominic Perrottet bid farewell to his 13-year career in parliament with a valedictory speech critiquing Covid-19 vaccine mandates as a “mistake”.
Perrottet, who recently announced his resignation from the seat of Epping to join mining giant BHP in Washington DC, asserted that strict vaccine mandates lacked consideration for personal freedoms despite their intentions.
“If the impact of vaccines on transmission was limited at best, as is mostly now accepted, the law should have left more room and respect for freedom,” he told parliament in his final speech.
“Without dwelling on every decision, I believe it’s important to point out one mistake which was made by governments here and around the world: the strict enforcement of vaccine mandates,” he said.
He acknowledged vaccines’ role in saving lives but emphasised the impact of mandates on individuals’ employment rights, declaring, “But ultimately mandates were wrong. People’s personal choices shouldn’t have cost them their jobs.”
Addressing broader governance issues, Perrottet advocated for fixed, four-year terms for federal governments to prioritise policy reform over perpetual campaigning.
His departure follows a tenure marked by his ascent to NSW’s youngest premier in 2021, succeeding Gladys Berejiklian.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More